JE
BMY icon

JMAC Enterprises’s Bristol-Myers Squibb BMY Stock Holding History

JMAC Enterprises’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,616
Closed -$431K – 116
2024
Q4 		$431K Buy
7,616
+237
+3% +$13.2K 0.07% 141
2024
Q3 		$382K Sell
7,379
-2,217
-23% -$104K 0.06% 144
2024
Q2 		$399K Sell
9,596
-1,059
-10% -$47.4K 0.07% 138
2024
Q1 		$578K Buy
10,655
+121
+1% +$6.16K 0.11% 119
2023
Q4 		$541K Sell
10,534
-1,637
-13% -$85.9K 0.12% 119
2023
Q3 		$706K Buy
12,171
+1,245
+11% +$76.3K 0.17% 102
2023
Q2 		$699K Buy
10,926
+1,281
+13% +$85.9K 0.17% 101
2023
Q1 		$668K Buy
9,645
+872
+10% +$61.5K 0.17% 103
2022
Q4 		$631K Sell
8,773
-714
-8% -$53.8K 0.17% 105
2022
Q3 		$674K Buy
9,487
+121
+1% +$8.78K 0.19% 108
2022
Q2 		$721K Sell
9,366
-223
-2% -$17K 0.19% 107
2022
Q1 		$700K Sell
9,589
-6,835
-42% -$459K 0.16% 105
2021
Q4 		$1.08M Buy
+16,424
New +$963K 0.25% 89

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JMAC Enterprises's BMY Position: Q1 2025 in Review

JMAC Enterprises sold out of Bristol-Myers Squibb (BMY) in Q1 2025, closing a stake of 7,616 shares — an estimated $431K sold.

JMAC Enterprises first reported a position in BMY in Q4 2021 and held it in 13 quarters. The position peaked at $1.08M in Q4 2021. 2,476 funds tracked by Wall St. Rank hold BMY as of Q1 2025.

  • JMAC Enterprises reported no remaining Bristol-Myers Squibb position as of Q1 2025 after selling out during the quarter.
  • JMAC Enterprises sold 7,616 Bristol-Myers Squibb shares in Q1 2025, an estimated $431K.
  • JMAC Enterprises first reported a position in Bristol-Myers Squibb in Q4 2021 and held it in 13 quarters.
  • JMAC Enterprises's Bristol-Myers Squibb position peaked at $1.08M in Q4 2021.
  • 2,476 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2025.

Based on JMAC Enterprises's 13F filing for Q1 2025, filed 22 Apr 2025.